888-416-9305 info@abterrabio.com

Truly human antibody therapeutics.

Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.

Our Services

Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!

Abterra Bio Reptor Hybridoma Sequencing

REPTOR™  

Next-Gen Sequencing Hybridoma

Abterra Bio Reptor Bulk B Cell Sequencing

REPTOR™  

Next-Gen Sequencing Bulk B Cells
Abterra Bio Reptor Hit Expansion

REPTOR™  

Next-Gen Sequencing Hit Expansion 
Abterra Bio Reptor Library Sequencing

REPTOR™  

Next-Gen Sequencing Display Library
Abterra Bio Alicanto Rabbit Antibody Discovery

ALICANTO®

Rabbit Monoclonal Antibody Discovery
Abterra Bio Alicanto Single Domain Antibody Discovery

ALICANTO®  

Single Domain (VHH) Antibody Discovery

Abterra Bio Alicanto Human Antibody Discovery

ALICANTO®

Human Antibody Discovery
Abterra Bio Valens Sequence Confirmation

VALENS™

Protein Sequence Confirmation
Abterra Bio Valens Antibody Protein Sequencing

VALENS™  

Antibody Protein Sequencing

Get In Touch

Tell Us About Your Project.

Need more information? We’re here to answer any questions you have.

What Our Partners Are Saying About Us

I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.

Sandeep Kumar, PhD

Associate Director - Antibody Discovery & Engineering, Scholar Rock

I would strongly recommend the services, Valens and Reptor, from Abterra Bio.  Not only were the individuals extremely helpful throughout the development of my project, but they were always available to answer any questions I had throughout the project.  Best of all, Abterra provided high-quality sequences with a rapid turnover which allowed my lab to continue our research with little delay.

Matthew Burchill, PhD

Assistant Professor, University of Colorado - Anschutz Medical Campus

I only have positive feedback. We expressed two of the antibodies and they worked wonderfully! We are very happy with the assay and saw a huge improvement over the hybridoma produced antibodies.

I will definitely come back to Abterra for my next sequencing project!

Associate Scientific Director - Translational Sciences

Leading Bioanalysis Company

Scientific Updates

Every day, we strive to help our partners and collaborators push the boundaries of their science.